Skip to content

Edgewise Therapeutics, Inc. EWTX Deferred Offering Costs Included In Accounts Payable And Accrued Other Expenses

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$4.18B+61.3%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept ewtx:DeferredOfferingCostsIncludedInAccountsPayableAndAccruedOtherExpenses.

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Edgewise Therapeutics, Inc.'s deferred offering costs included in accounts payable and accrued other expenses?
Edgewise Therapeutics, Inc. (EWTX) reported deferred offering costs included in accounts payable and accrued other expenses of $395K in Q1 2025.